Answers are grounded in this paper and cite their sources.
Single-centre cohort study shows PD-1/CD3% distinguishes immune-related adverse events in patients, indicating potential for better management.
Distinguishing maculopapular immune-related adverse events (irAE) from conventional drug eruptions (DE) can be difficult because of overlapping clinicopathological features. In this single-centre retrospective cohort, the proportion of PD-1-positive cells among CD3-positive T cells (PD-1/CD3%) showed complete separation between groups and may provide an objective adjunct to routine histopathological assessment. This simple metric may support clinicopathological attribution and inform management decisions in patients receiving immunotherapy.
No takes yet. Share an insight, caveat, or question.
Ikuno et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: